據報默沙東新冠口服藥今於內地上市銷售 首發報價每瓶1,500人幣
《中國證券報》報道,國藥控股(01099.HK)總裁劉勇日前透露,由該公司代理的默沙東新冠口服藥莫諾拉韋已通過首次進口的藥品檢驗,預計今日(13日)在內地首發。據悉,有關藥物上市後將通過醫療機構渠道進行配藥銷售。
根據天津市醫藥採購中心發布消息,受天津市醫療保障局委託,天津市醫藥採購中心將杭州默沙東製藥有限公司申報的莫諾拉韋膠囊首發報價等有關信息進行公示,新冠治療藥品莫諾拉韋膠囊首發報價為每瓶1,500元人民幣,每瓶有40粒藥物。
《新型冠狀病毒感染診療方案(試行第十版)》規定,所有治療性藥物,包括Paxlovid、阿茲夫定片、莫諾拉韋膠囊、散寒化濕顆粒等,醫保都將臨時性支付到今年3月31日。該藥也是繼輝瑞Paxlovid、河南真實生物阿茲夫定之後,第三款在內地獲批的新冠口服藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.